Aclaris Therapeutics Completes Enrollment Of 109 Patients In Phase 2 Trial Of Bosakitug For Moderate-To-Severe Atopic Dermatitis, Top Line Results Due Q4 2026

Benzinga Newsdesk www.benzinga.com Positive 87.2%

Neg 0% Neu 0% Pos 87.2%

Comments

No comments yet. Be the first!